Rsv bronchiolitis
Pro Research Analysisby 
Searched over 200M research papers for "rsv bronchiolitis"
RSV Bronchiolitis: Causes, Impacts, and Long-term Effects
Introduction to RSV Bronchiolitis
Respiratory Syncytial Virus (RSV) Bronchiolitis is a leading cause of lower respiratory tract infections in infants and young children. It is characterized by the obstruction and inflammation of the small bronchiolar airways, leading to symptoms such as wheezing and reduced airflow . RSV is the most common viral agent responsible for bronchiolitis, often resulting in hospitalizations among previously healthy infants .
Risk Factors and Severity
RSV-A vs. RSV-B
Research indicates that the severity of bronchiolitis can vary depending on the RSV subtype. For instance, RSV-A infections have been associated with more severe outcomes, including a higher need for intensive care and respiratory support, compared to RSV-B infections . This differentiation is crucial for clinical evaluation and healthcare planning during RSV seasons.
Long-term Respiratory Issues
RSV bronchiolitis in infancy has been linked to long-term respiratory issues, including recurrent wheezing and asthma. Studies show that children who had RSV bronchiolitis are at a significantly higher risk of developing asthma and allergic sensitization later in life 39. Up to 40% of children with RSV bronchiolitis report wheezing within five years post-infection, compared to only 11% in control groups . This risk persists, albeit at a reduced rate, up to ten years after the initial infection.
Treatment and Prevention
Current Treatment Modalities
The treatment for RSV bronchiolitis primarily focuses on symptomatic support. Despite the frequent use of beta-agonists, nebulized racemic epinephrine, hypertonic saline, and corticosteroids, there is limited evidence supporting their effectiveness in reducing hospital admissions or the length of hospital stay .
Novel Therapies
Recent trials have explored the efficacy of new treatments. For example, ALN-RSV01, a small interfering RNA targeting RSV replication, has shown promise in reducing the incidence of bronchiolitis obliterans syndrome (BOS) in lung transplant recipients . Additionally, clarithromycin has demonstrated significant effects in reducing hospital stay duration and the need for supplemental oxygen in infants with RSV bronchiolitis .
Immunoprophylaxis and Vaccination
Passive immunoprophylaxis with monoclonal antibodies against RSV has proven effective in preventing severe RSV bronchiolitis in high-risk children, such as those born prematurely or with chronic lung disease . Moreover, maternal vaccination is being considered as a promising approach to protect infants, given the challenges in developing a direct vaccine for young children .
Conclusion
RSV bronchiolitis remains a significant health concern for infants and young children, with potential long-term respiratory complications. While current treatments focus on symptomatic relief, ongoing research into novel therapies and preventive measures, including immunoprophylaxis and maternal vaccination, offers hope for better management and reduction of RSV-related morbidity. Understanding the epidemiology and molecular characteristics of RSV can further aid in developing targeted interventions to mitigate the impact of this pervasive virus.
Sources and full results
Most relevant research papers on this topic
The role of respiratory syncytial virus‐ and rhinovirus‐induced bronchiolitis in recurrent wheeze and asthma—A systematic review and meta‐analysis
Rhinovirus-induced bronchiolitis is a stronger risk factor for recurrent wheeze and asthma in children than RSV-induced bronchiolitis.
ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients.
ALN-RSV01 reduces the risk of bronchiolitis obliterans syndrome (BOS) after respiratory syncytial virus infection in lung transplant recipients, confirming earlier findings.
DOI